Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma

Published:2005-01-20 Issue:3 Volume:174 Page:1709-1716
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Bricard Gabriel,Bouzourene Hanifa,Martinet Olivier,Rimoldi Donata,Halkic Nermin,Gillet Michel,Chaubert Pascal,MacDonald H. Robson,Romero Pedro,Cerottini Jean-Charles,Speiser Daniel E.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference45 articles.

1. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials

2. Hepatocellular Carcinoma

3. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

4. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer

5. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs);Journal of Experimental & Clinical Cancer Research;2024-03-20

2. Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients;OncoImmunology;2022-10-05

3. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies;International Journal of Molecular Sciences;2022-09-02

4. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?;International Journal of Molecular Sciences;2022-02-11

5. Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia;Molecular Therapy - Methods & Clinical Development;2021-12